Roberta K. Sefcik
Research Subjects
Roberta K. Sefcik has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Andrea D. Branch
Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York
1 shared publication- Christopher Paul Kellner
Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, New York, USA
1 shared publication Douglas T. Dieterich
Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York
1 shared publicationJ Mocco
Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, New York; and
1 shared publicationJawad Ahmad
Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York
1 shared publicationJoseph A. Odin
Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York
1 shared publication
Latest Publications
- 1 May 2016
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Neurosurgical Focus
- Vol. 40 (5) , E7
The evolution of endovascular electroencephalography: historical perspective and future applications
Current standard practice requires an invasive approach to the recording of electroencephalography (EEG) for epilepsy surgery, deep brain stimulation (DBS), and brain-machine interfaces (BMIs). The development of endovascular techniques offers a minimally invasive route to recording EEG from deep brain structures. This historical perspective aims to describe the technical progress in endovascular EEG by reviewing the first endovascular recordings made using a wire electrode, which was followed by the development of nanowire and catheter recordings and, finally, the most recent progress in stent-electrode recordings. The technical progress in device technology over time and the development of the ability to record chronic intravenous EEG from electrode arrays is described. Future applications for the use of endovascular EEG in the preoperative and operative management of epilepsy surgery are then discussed, followed by the possibility of the technique's future application in minimally invasive operative approaches to DBS and BMI.
- 1 May 2016
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Neurosurgical Focus
- Vol. 40 (5) , E7
The evolution of endovascular electroencephalography: historical perspective and future applications
Current standard practice requires an invasive approach to the recording of electroencephalography (EEG) for epilepsy surgery, deep brain stimulation (DBS), and brain-machine interfaces (BMIs). The development of endovascular techniques offers a minimally invasive route to recording EEG from deep brain structures. This historical perspective aims to describe the technical progress in endovascular EEG by reviewing the first endovascular recordings made using a wire electrode, which was followed by the development of nanowire and catheter recordings and, finally, the most recent progress in stent-electrode recordings. The technical progress in device technology over time and the development of the ability to record chronic intravenous EEG from electrode arrays is described. Future applications for the use of endovascular EEG in the preoperative and operative management of epilepsy surgery are then discussed, followed by the possibility of the technique's future application in minimally invasive operative approaches to DBS and BMI.
- Open Access
- 26 June 2014
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 210 (11) , 1855-1856
Telaprevir Activity in Treatment-Naive Patients Infected With Hepatitis C Virus Genotype 4
To the Editor—Benhamou et al demonstrated that the tolerability and pharmacokinetics of telaprevir in patients infected with hepatitis C virus (HCV) genotype 4 were similar to those found in HCV genotype 1 patients [1]. In their study, patients infected with HCV genotype 4 were randomly assigned to receive (1) telaprevir monotherapy for 15 days; (2) telaprevir, pegylated interferon alfa-2a, and ribavirin (TPR) for 15 days; or (3) placebo, pegylated interferon alfa-2a, and ribavirin (PR) for 15 days. After the initial 15-day treatment period, study drugs in each group were replaced with standard PR treatment, which was administered for an additional 46–48 weeks.
- 26 June 2014
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 210 (11) , 1855-1856
Open AccessTelaprevir Activity in Treatment-Naive Patients Infected With Hepatitis C Virus Genotype 4
To the Editor—Benhamou et al demonstrated that the tolerability and pharmacokinetics of telaprevir in patients infected with hepatitis C virus (HCV) genotype 4 were similar to those found in HCV genotype 1 patients [1]. In their study, patients infected with HCV genotype 4 were randomly assigned to receive (1) telaprevir monotherapy for 15 days; (2) telaprevir, pegylated interferon alfa-2a, and ribavirin (TPR) for 15 days; or (3) placebo, pegylated interferon alfa-2a, and ribavirin (PR) for 15 days. After the initial 15-day treatment period, study drugs in each group were replaced with standard PR treatment, which was administered for an additional 46–48 weeks.